Lv1
88 积分 2025-02-23 加入
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
5天前
已完结
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
5天前
已完结
Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy
6天前
已完结
Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
10天前
已完结
Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States
11天前
已完结
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia
11天前
已关闭
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
11天前
已关闭
HSR25-164: Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia – A Study From the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas & CLL
11天前
已关闭
Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia
12天前
已完结
How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy
16天前
已完结
皖公网安备34019202002308
